Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes

Documenti analoghi

• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  di: David C. Klonoff, et al.
  Pubblicazione: (2024)
• Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan
  di: Yu‐Hsin Yen, et al.
  Pubblicazione: (2024)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  di: Yunwen Xu, et al.
  Pubblicazione: (2025)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  di: Darren Lau, et al.
  Pubblicazione: (2024)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  di: Filip K. Knop, et al.
  Pubblicazione: (2024)